Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Genetically engineered T cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistence

Genetically engineered T cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistence

US Patent 11679131 · Granted Jun 20, 2023

Estimated economic value: $30,298,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Genetically engineered T cells having improved persistence in culture2025
Methods and compositions for treating cancer2025
Methods and compositions for treating cancer2025
Genetically engineered T cells with Regnase-1 and/or TGFBRII disruption have imp2024
Genetically engineered T cells with Regnase-1 and/or TGFBRII disruption have imp2024
Genetically engineered T cells with Regnase-1 and/or TGFBRII disruption have imp2024
Anti-idiotype antibodies targeting anti-CD70 chimeric antigen receptor2023
Genetically engineered t cells with Regnase-1 and/or TGFBRII disruption have imp2023
Genetically engineered t cells with Regnase-1 and/or TGFBRII disruption have imp2023
Genetically engineered t cells with Regnase-1 and/or TGFBRII disruption have imp2023
Methods and compositions for treating cancer2023
Methods and compositions for treating cancer2023